August 28th, 2013
Platelet Reactivity Testing: Do You or Don’t You?
Richard A. Lange, MD, MBA and L. David Hillis, MD
In light of recent findings from the ADEPT DES study, Richard Lange and David Hillis want to know: Do you test PCI patients for platelet reactivity, and if so, why? React to reactivity in our latest poll.
January 18th, 2012
Cangrelor and Alaska’s “Bridge to Nowhere”
Richard A. Lange, MD, MBA and L. David Hillis, MD
The Gravina Island Bridge (also known as The Bridge to Nowhere) was a proposed bridge to replace the ferry that currently connects Ketchikan, Alaska (population, 14,000) to the Ketchikan International Airport on Gravina Island (population, 50) at a projected cost of $398 million. The bridge was to have been nearly as long as the Golden Gate […]
November 16th, 2010
GRAVITAS: No Benefit for Clopidogrel Dosing Based on Platelet Function Test
Larry Husten, PHD
The GRAVITAS (Gauging Responsiveness With A VerifyNow Assay ─ Impact on Thrombosis and Safety) trial enrolled 2214 patients with high residual platelet reactivity, as assessed by the VerifyNow P2Y12 Test measured 12 to 24 hours after the procedure. (The manufacturer of the test, Accumetrics, sponsored the trial.) Patients in the trial were randomized to either high-dose clopidogrel […]
NEJM Journal Watch — Recent Cardiology Articles- Is Diltiazem Safe in Patients with AF Taking Apixaban or Rivaroxaban?
- Does Lowering High Childhood Lipid Levels Prevent Adverse Cardiovascular Events in Adulthood?
- Self-Expanding Supraannular Valve vs. Balloon-Expandable Valve in TAVR for Small Aortic Annulus
- A New TAVR Prosthesis for Aortic Regurgitation Shows Promise
- Aprocitentan, a Newly Approved Drug for Resistant Hypertension